Breast Cancer Imaging Using 18F-Fluoroestradiol
Sponsored by the SNMMI PET Center of Excellence
Twyla B. Bartel, DO, MBA, FACNM
Amy M. Fowler, MD, PhD
University of Wisconsin, Madison, WI
18F-fluoroestradiol (18F-FES) was approved in 2020 by the U.S. FDA for molecular imaging of breast cancer. The purpose of this presentation is to discuss recommendations for performing and interpreting 18F-FES PET/CT and how 18F-FES PET imaging adds to the clinical management of patients with breast cancer. The intended audience is primarily nuclear medicine physicians and radiologists who interpret PET imaging.
1. Describe the FDA approved indication for use of 18F-FES PET imaging.
2. Identify physiologic and abnormal 18F-FES uptake.
3. Discuss limitations and diagnostic challenges of 18F-FES PET imaging.
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.